Standard & complex BE
Conventional, replicate and partial-replicate designs, including highly variable drugs and challenging formulations.
Start a conversation ↗Scientific expertise
Scientific depth and connected delivery for programmes that demand more than routine execution.
Integrated thinking
Questra brings clinical operations, bioanalysis, regulatory science, data and reporting together around each product’s development question.
Our teams design fit-for-purpose approaches for conventional and complex bioequivalence studies, early clinical development, specialised analytical programmes and products that require tailored evidence pathways.
By considering clinical feasibility, analytical performance, operational risk and regulatory expectations together, we help sponsors identify challenges earlier and build stronger, more coherent evidence packages.
Conventional, replicate and partial-replicate designs, including highly variable drugs and challenging formulations.
Tailored scientific and regulatory evidence for fixed-dose combinations, bridging strategies and hybrid applications.
PK/PD strategy, DDI evaluation, early-phase execution and specialised analytical planning.
LC–MS/MS method development, validation and quantitative sample analysis for small molecules.
Data management, pharmacokinetic calculation, statistical analysis and integrated interpretation.
ICH-GCP-aligned clinical operations, GLP expertise, quality assurance and risk-based oversight.
End-to-end delivery
Capabilities can be combined into an integrated programme or selected to strengthen a specific stage of development.